Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: A double-blind, randomized, dose-ranging trial

American Journal of Therapeutics

Volumn 18, Issue 3, 2011, Pages 216-226

  DeLemos, Byron P ^a   Xiang, Jim ^a   Benson, Carmela ^a   Gana, Theophilus J ^b   Pascual, Maria Luz G ^c   Fleming, R Rosanna B ^c  

^a Ortho McNeil Pharmaceutical Incorporated   (United States)

^b Biopharmatech Consulting Inc   (United States)

^c Biovail Corporation   (Canada)

Author keywords

osteoarthritis; pain; tramadol

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; PARACETAMOL; PLACEBO; TRAMADOL;

ABDOMINAL CRAMP; ADULT; AGED; ANOREXIA; ARTICLE; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EUPHORIA; FATIGUE; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; GOOSEFLESH; HEART RATE; HIP OSTEOARTHRITIS; HUMAN; INSOMNIA; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINORRHEA; SHIVERING; SIDE EFFECT; SLEEP QUALITY; SNEEZING; SOMNOLENCE; TABLET FORMULATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; VOMITING; XEROSTOMIA; YAWNING;

ADULT; AGED; ANALGESICS, OPIOID; CYCLOOXYGENASE 2 INHIBITORS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; PLACEBOS; PYRAZOLES; SULFONAMIDES; TRAMADOL; YOUNG ADULT;

EID: 79958038852     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181cec307     Document Type: Article

References (28)

1. Rabenda V, Manette C, Lemmens R, et al. Prevalence and impact of osteoarthritis and osteoporosis on healthrelated quality of life among active subjects. Aging Clin Exp Res. 2007;19:55-60. (Pubitemid 46534222)
2. Dawson J, Linsell L, Zondervan K, et al. Impact of persistent hip or knee pain on overall health status in elderly people: a longitudinal population study. Arthritis Rheum. 2005;53:368-374. (Pubitemid 40799875)
3. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992;260:275-285.
4. Altman RA, Hochberg MC, Moskowitz RW, et al. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000;43: 1905-1915.
5. Jensen EM, Ginsberg F. Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double-blind study. Drug Invest. 1994;8:211-218. (Pubitemid 24319459)
6. Roth SH. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol. 1998;25:1358-1363. (Pubitemid 28312355)
7. Schnitzer TJ, Kamin M, Olson WH. Tramadol allows reduction of naproxen dose among patients with naproxenresponsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 1999;42:1370-1377. (Pubitemid 30265594)
8. Fleischmann RM, Caldwell JR, Roth SH, et al. Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Curr Ther Res. 2001;62:113-128. (Pubitemid 32222928)
9. Cepeda MS, Camargo F, Zea C, et al. Tramadol for osteoarthritis: a systematic review and meta-analysis. J Rheumatol. 2007;34:543-555. (Pubitemid 46364009)
10. Mullican WS, Lacy JR. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clin Ther. 2001;23:1429-1445. (Pubitemid 32912792)
11. ULTRAM® ER (tramadol HCl) Extended-Release Tablets Prescribing Information. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc; 2006.
12. Vorsanger GJ, Xiang J, Gana TJ, et al. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag. 2008;4:87-97. (Pubitemid 351836603)
13. Babul N, Noveck R, Chipman H, et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage. 2004;28:59-71. (Pubitemid 38829673)
14. Gana TJ, Pascual MLG, Fleming RRB, et al. Extendedrelease tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin. 2006;22:1391-1401. (Pubitemid 44085591)
15. Pascual MLG, Fleming RRB, Gana TJ, et al. Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain. Curr Med Res Opin. 2007;23: 2531-2542. (Pubitemid 350033455)
16. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum. 1995;38:1535-1540.
17. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995;38:1541-1546.
18. Bellamy N. WOMAC Osteoarthritis Index: User Guide IV. Queensland, Australia: WOMAC; 2000.
19. Kosinski M, Janagap CC, Gajria K, et al. Psychometric testing and validation of the Chronic Pain Sleep Inventory. Clin Ther. 2007;(29 Suppl):2562-2577. (Pubitemid 350299456)
20. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
21. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-263.
22. Haertzen CA. Addiction Research Center Inventory (ARCI): development of a general drug estimation scale. J Nerv Ment Dis. 1965;141:300-307.
23. Brady JV, Lukas SE, eds. Testing Drugs for Physical Dependence Potential and Abuse Liability: NIDA Research Monograph 52. Rockville, MD: National Institute on Drug Abuse; 1984.
24. Koshi EB, Short CA. Placebo theory and its implications for research and clinical practice: a review of the recent literature. Pain Pract. 2007;7:4-20.
25. Murthy BP, Skee DM, Danyluk AP, et al. Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol. Curr Med Res Opin. 2007;23:275-284. (Pubitemid 46333375)
26. Malonne H, Coffiner M, Sonet B, et al. Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004;26:1774-1782. (Pubitemid 40089490)
27. Cicero TJ, Inciardi JA, Adams EH, et al. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf. 2005;14:851-859. (Pubitemid 43056111)
28. Adams EH, Breiner S, Cicero TJ, et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage. 2006; 31:465-476. (Pubitemid 43744403)